Immunotherapy at the diabetes 2 types, complicated by the syndrome of diabetic foot, by the complex of natural cytokines and antimicrobial peptides


Cite item

Abstract

In research results of inspection and treatment of 75 patients with DFS are analysed. Patients are divided into 2 investigated groups depending on character of disease and treatment schemes. The first group have made 25 (33,3 %) patients
by whom treatment under the traditional scheme (antibacterial therapy, disaggregants, angioprotectors, antioxidants,
correction level of hyperglycemia, surgical treatment, bandagings with ointment of Levomekol was spent). In the second
group are included 50 (66,7 %) patients with purulent-necrotic defeats of foot, in which treatment, along with the standard
methods, it was used immunecorrection by a preparation "Superlimf". The control group of 25 persons is presented by
healthy people. It is established that application immunotherapy by complex natural cytokines and antimicrobial peptides
at a diabetes 2 types, complicated by the diabetic foot syndrome, pathogenetic is proved. Оbserved decrease of activity of
processes lipid peroxidation was, stabilization in antioxidant blood protection, decrease endogenous intoxication, normalisation of phagocytic a component of immune system, level of circulating immunoglobulin in blood. At patients about a
syndrome of diabetic foot immunecorrection a preparation "Superlimf" is a choice method immunomodelling therapies

About the authors

Leonid Vasilyevich Kovalchuk

Russian state medical University. N. I.Pirogov

Author for correspondence.
Email: bruda_elf@mail.ru

 MD, Professor,  academician of RANS, head of Department of immunology

Russian Federation, Russia, Moscow, street Ostrovitjanova, 1s7

Vladimir Vasilievich Potemkin

Russian state medical University. N. I.Pirogov

Email: bruda_elf@mail.ru

 PhD, Professor, head of Department of endocrinology

Russian Federation, Russia, Moscow, street Ostrovitjanova, 1s7

Tatiana Nikolaevna Baldina

Russian state medical University. N. I.Pirogov

Email: bruda_elf@mail.ru

 postgraduate student of the Department  endocrinology

Russian Federation, Russia, Moscow, street Ostrovitjanova, 1s7

Pavel Borisovich Barbin

Institute of surgery. A. V. Vishnevsky

Email: bruda_elf@mail.ru

 postgraduate student of the Department of AB-dominale surgery

Russian Federation, Russia, Moscow, street Ostrovitjanova, 1s7

References

  1. Горшков И.П., Золоедов В.И,, Волынкина А.П. Применение актовегина в лечении диабетической полинейропатии и профилактике синдрома диабетической стопы у больных хирургического профиля с сахарным диабетом 2 типа и артериальной гипертерзией. Вестник экспериментальной и клинической хирургии 2010; 3: 3: 260-264.
  2. Гостищев В.К, Хохлов А.М., Афанасьев А.Н. и др. Комплексная диагностика и лечение диабетических остеоартропатий. 1 Белорусский международный конгресс
  3. хирургов. Витебск 1996: 379-380.
  4. Григорян А.В., Оганесян С.С. Гнойные заболевания и гангрены конечностей при сахарном диабете. Ереван
  5. ; 126.
  6. Гриневич А.С., Андреев И.В., Мартынов А.И. Структурно-функциональные особенности углеводов иммуноглобулинов в норме и патологии. Иммунология 1994;3: 10-15.
  7. Дедов И.И., Анциферов М.Б., Токмакова А.Ю. Синдром
  8. диабетической стопы. Клиническая фармакология и терапия 1993; 3: 58-62.
  9. Дедов И.И., Абугова И.А., Шахмалова М.Ш., Шишко П.И. Иммунотерапия при инсулинозависимом сахарном диабете. Пробл. эндокринол. 1995; 4: 43-48.
  10. Дедов И.И., Чугунова Л.А., Смирнова О.М. и др. Особенности клеточного иммунитета у больных с впервые выявленным инсулинозависимым сахарным диабетом. Пробл. эндокринол. 1994; 1: 17-20.
  11. Ефимов А.С., Науменко В.Г. Перекисное окисление липидов в эритроцитах больных сахарным диабетом с диабетическими ангиопатиями. Пробл. эндокринологии 1985; 1: 6-9.
  12. King, G. L., and Brownlee, M. The cellular and molecular mechanisms of diabetic complications. Endocrinol. Metab. Clin. North. Am. 1996; 25: 255–270.
  13. Tanaka, S., Seino, H., Satoh, J., Fujii, N., Rikiishi, H., Zhu, X. P.,Takahashi, K., Sagara, M., Nobunaga, T., and Toyota, T. Increased in vivo production of tumor necrosis factor after development of diabetes in nontreated, long-term diabetic BB rats. Clin. Immunol. Immunopathol. 1992; 62: 258–263.
  14. Katsuki, A., Sumida, Y., Murashima, S., Murata, K., Takarada, Y., Ito, K., Fujii, M., Tsuchihashi, K., Goto, H., Nakatani, K., and Yano, Y. Serum levels of tumor necrosis factoralpha are increased in obese patients with noninsulindependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1998; 83: 859–862.
  15. Morohoshi, M., Fujisawa, K., Uchimura, I., and Numano, F. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes. 1996; 45: 954–959

Copyright (c) Kovalchuk L.V., Potemkin V.V., Baldina T.N., Barbin P.B.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies